Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

Bayer meanwhile recently started a fourth phase 3 trial of elinzanetant that will test the drug's ability to treat VMS associated with endocrine therapy of breast cancer. GlobalData recently ...

Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones. The deal covers certain uses of drug candidate aficamten in hypertrophic ...

Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

TheUS Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for its oral androgen receptor inhibitor (ARi), for the treatment of patients with ...

With Eylea biosimilar competition creeping in and Roche’s Vabsymo jockeying for market share in key indications, Regeneron is ...

Successful drug development is imperative to Bayer amid multiple challenges. The failure of a late-stage study on asundexian was a major setback for the company. BAYRY is also working to expand ...